Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is based in Irvine, California. more
Time Frame | CGON | Sector | S&P500 |
---|---|---|---|
1-Week Return | -2.94% | -3.35% | -2.97% |
1-Month Return | -14.57% | -3.49% | -0.66% |
3-Month Return | -28.36% | -12.6% | 2.71% |
6-Month Return | -12.74% | -6.91% | 7.21% |
1-Year Return | -24.62% | 1.19% | 23.04% |
Dec '21 | Dec '22 | Dec '23 | ||||
---|---|---|---|---|---|---|
Total Revenue | 10.36M | 191.00K | 204.00K | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":1.84,"profit":true},{"date":"2023-12-31","value":1.97,"profit":true}] | ||
Cost of Revenue | 10.00K | 15.00K | 45.75M | [{"date":"2021-12-31","value":0.02,"profit":true},{"date":"2022-12-31","value":0.03,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Gross Profit | 10.35M | 176.00K | 204.00K | [{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":1.7,"profit":true},{"date":"2023-12-31","value":1.97,"profit":true}] | ||
Gross Margin | 99.90% | 92.15% | 100.00% | [{"date":"2021-12-31","value":99.9,"profit":true},{"date":"2022-12-31","value":92.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Operating Expenses | 22.95M | 35.42M | 55.65M | [{"date":"2021-12-31","value":41.24,"profit":true},{"date":"2022-12-31","value":63.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] | ||
Operating Income | (12.61M) | (35.25M) | (55.45M) | [{"date":"2021-12-31","value":-1260600000,"profit":false},{"date":"2022-12-31","value":-3524600000,"profit":false},{"date":"2023-12-31","value":-5544900000,"profit":false}] | ||
Total Non-Operating Income/Expense | (684.00K) | (198.00K) | 13.75M | [{"date":"2021-12-31","value":-4.98,"profit":false},{"date":"2022-12-31","value":-1.44,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] | ||
Pre-Tax Income | (12.84M) | (35.44M) | (48.61M) | [{"date":"2021-12-31","value":-1283900000,"profit":false},{"date":"2022-12-31","value":-3544300000,"profit":false},{"date":"2023-12-31","value":-4860700000,"profit":false}] | ||
Income Taxes | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Income After Taxes | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Income From Continuous Operations | (12.84M) | (35.44M) | (48.61M) | [{"date":"2021-12-31","value":-1283900000,"profit":false},{"date":"2022-12-31","value":-3544300000,"profit":false},{"date":"2023-12-31","value":-4860700000,"profit":false}] | ||
Income From Discontinued Operations | - | - | - | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] | ||
Net Income | (12.84M) | (35.44M) | (48.61M) | [{"date":"2021-12-31","value":-1283900000,"profit":false},{"date":"2022-12-31","value":-3544300000,"profit":false},{"date":"2023-12-31","value":-4860700000,"profit":false}] | ||
EPS (Diluted) | - | - | (0.33) | [{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":-33.09,"profit":false}] | ||
These ratios help you determine the liquidity of the company. Higher is better.
CGON | |
---|---|
Cash Ratio | 34.59 |
Current Ratio | 35.32 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CGON | |
---|---|
ROA (LTM) | -15.70% |
ROE (LTM) | -19.76% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CGON | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.03 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.97 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CGON | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 3166.51 |
P/B | 4.04 |
Price/FCF | NM |
EV/R | 2376.43 |
EV/Ebitda | NM |
CG Oncology, Inc. Common stock (CGON) share price today is $28.02
Yes, Indians can buy shares of CG Oncology, Inc. Common stock (CGON) on Vested. To buy CG Oncology, Inc. Common stock from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CGON stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of CG Oncology, Inc. Common stock (CGON) via the Vested app. You can start investing in CG Oncology, Inc. Common stock (CGON) with a minimum investment of $1.
You can invest in shares of CG Oncology, Inc. Common stock (CGON) via Vested in three simple steps:
The 52-week high price of CG Oncology, Inc. Common stock (CGON) is $50.23. The 52-week low price of CG Oncology, Inc. Common stock (CGON) is $25.77.
The price-to-earnings (P/E) ratio of CG Oncology, Inc. Common stock (CGON) is
The price-to-book (P/B) ratio of CG Oncology, Inc. Common stock (CGON) is 4.04
The dividend yield of CG Oncology, Inc. Common stock (CGON) is 0.00%
The market capitalization of CG Oncology, Inc. Common stock (CGON) is $2.17B
The stock symbol (or ticker) of CG Oncology, Inc. Common stock is CGON